# A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas

> **NCT00274651** · PHASE2 · TERMINATED · sponsor: **Valerio Therapeutics** · enrollment: 53 (actual)

## Conditions studied

- Cutaneous T-Cell Lymphoma
- Peripheral T-Cell Lymphoma
- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** belinostat

## Key facts

- **NCT ID:** NCT00274651
- **Lead sponsor:** Valerio Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-01
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 53 (ACTUAL)
- **Why stopped:** Enrollment stopped prior to reaching expected number of patients, study had accumulated sufficient data to allow a registration study in PTCL (PXD101-CLN-19)
- **Last updated:** 2015-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00274651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00274651, "A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00274651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*